2,794 results on '"Schmid Christoph"'
Search Results
152. CD6-negative, G-CSF-mobilized blood cells facilitate engraftment of HLA-haploidentical marrow and suppress GvHD in high-risk hematopoietic neoplasia
153. Allogeneic stem cell transplantation after chemotherapy and dose reduced-intensity conditioning for high-risk AML and MDS
154. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial
155. Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
156. Interferometric carrier-envelope phase stabilization for ultrashort pulses in the mid-infrared
157. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia
158. The Gravito–Maxwell equations of General Relativity in the local reference frame of a GR-noninertial observer
159. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukemia - a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).
160. Non-T Depleted Haploidentical Transplantation with Post-Transplantation Cyclophosphamide in Patients with Secondary Versus De Novo AML: A Study from the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
161. Clocking Correlations between Bloch Electrons on the Attosecond Time Scale
162. BPACE: A Bayesian, Patient-Centered Procedure for Matrix Speech Tests in Noise
163. Reduced 8-Gray Compared to Standard 12-Gray Total Body Irradiation for Allogeneic Transplantation in First Remission Acute Lymphoblastic Leukemia: A Study of the Acute Leukemia Working Party of the EBMT
164. Total body irradiation/fludarabine versus busulfan/fludarabine as conditioning in all patients > 45 years in 1sr CR - a registry-based study by the ALWP of the EBMT [Abstract]
165. Feasibility and results of prophylactic donor lymphocyte transfusion following allogeneic stem cell transplantation with reduced-conditioning for high-risk AML and MDS
166. Allogeneic stem cell transplantation in myelofibrosis with myeloid metaplasia: german multicentre analysis supports early transplantation
167. Favorable results of prophylactic donor lymphocyte transfusions following allogeneic stem cell transplantation after reduced intensity conditioning for high-risk AML and MDS [Abstract]
168. Long-lasting remissions in high-risk AML and MDS following sequential therapy with chemotherapy, reduced-intensity conditioning for allogeneic transplantation, and prophylactic DLT
169. An unexpected and ultimately fatal cause of extensive unilateral proptosis in a patient with secondary acute myeloid leukemia [Abstract]
170. Polymorphism in the promoter region of the hemeoxygenase I gene of the donor influences overall survival and graft-versus-host disease
171. Allogeneic stem cell transplantation in AML and MDS - reduced conditioning for increased risk? The Munich/AMLCG approach
172. Graft-versus-leukaemia reaction in HLA-haploidentical transplantation using the combination of unmodified marrow and CD6-depleted G-CSF mobilised blood cells
173. Generability and quality of leukaemia-derived DC (DCleu) in AML or MDS: conditions and consequences
174. Treatment of high-risk AML and MDS with ara-C containing standard chemotherapy followed by reduced-intensity conditioning allogeneic stem cell transplantation during aplasia: a survey of the German Cooperative Transplant Study Group (GCTSG)
175. In patients over 50 years with intermediate or high-risk AML survival after allogeneic stem cell transplantation is not dependent on donor type (matched unrelated versus sibling donors)
176. Role of the quality and quantity of (leukaemia-derived) dendritic cells and anti-leukaemia-directed T-cells to predict the course and success of immunotherapy
177. Dendritic Cell-Triggered Immune Activation Goes along with Provision of (Leukemia-Specific) Integrin Beta 7-Expressing Immune Cells and Improved Antileukemic Processes
178. Retrospective analysis of hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: conditioning intensity matters
179. Growth hormone secreting pituitary microadenomas and empty sella – An under-recognized association?
180. Introduction
181. The role of tenancy law in the tenant countries Switzerland, Austria and Germany – macroeconomic benefits through a balanced legal infrastructure?
182. Loss of Homes and Evictions across Europe
183. Tenancy Law and Housing Policy in Europe
184. Response to “Going beyond scoring systems for cavernous sinus involvement in trans-sphenoidal pituitary surgery”
185. Chapter L.1: Lease contracts and tenancies
186. Proceedings from the National Cancer Institute’s Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: Part III. Prevention and Treatment of Relapse after Allogeneic Transplantation
187. Impact of honey on dental erosion and adhesion of early bacterial colonizers
188. Palliative Care – Konzepte bei hämatologischen Patienten
189. Immunotherapy
190. Long-term survival in patients suffering from AML with a complex aberrant karyotype after early allogeneic stem cell transplantation using the FLAMSA-RIC regimen: results from a prospective phase II trial
191. Characterization and T-cell repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - data from the phase 1 trial in patients with relapsed or refractory B-cell non-hodgkin lymphoma [Abstract]
192. Separating patients with myelofibrosis with myeloid metaplasia into risk groups for allogeneic haematopoietic cell transplantation – results of a German multicentre analysis
193. ALWP registry and achievements
194. Management of relapse after allogeneic HSCT for AML using reduced-intensity conditioning (RIC): a common study by the ALWP subcommittees on immunotherapy and RIC
195. Role of iron overload for the outcome of allogeneic stem cell transplantation in high-risk acute myeloid leukaemia and myelodysplastic syndrome [Abstract]
196. RIC for AML: a decade later
197. Second allogeneic stem cell transplantation using reduced-intensity conditioning for acute myeloid leukaemia patients who relapsed following a first RIC allo-SCT: a survey from the Acute Leukaemia Working Party of EBMT [Abstract]
198. Management and outcome of myelodysplastic syndrome (MDS) and secondary acute myeloid leukaemia relapsing after allogeneic stem cell transplantation: a retrospective analysis on 888 patients by the MDS Subcommittee of the EBMT Chronic Leukaemia Working Party
199. Allogeneic stem cell transplantation in acute myeloid leukaemia with normal karyotype: a risk factor analysis in 247 patients, based on molecular markers and stage at transplantation [Abstract]
200. Developing Centers Subcommittee: centre experience and results of allo-HSCT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.